BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kamata N, Oshitani N, Watanabe K, Watanabe K, Hosomi S, Noguchi A, Yukawa T, Yamagami H, Shiba M, Tanigawa T, Watanabe T, Tominaga K, Fujiwara Y, Arakawa T. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response. Dig Dis Sci 2015;60:1382-8. [PMID: 25532505 DOI: 10.1007/s10620-014-3493-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Hirai F, Takeda T, Takada Y, Kishi M, Beppu T, Takatsu N, Miyaoka M, Hisabe T, Yao K, Ueki T. Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. J Gastroenterol 2020;55:133-41. [PMID: 31641874 DOI: 10.1007/s00535-019-01634-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
2 Takeshima F, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Machida H, Matsushima K, Minami H, Akazawa Y, Yamaguchi N, Ohnita K, Isomoto H, Ueno M, Nakao K. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. BMC Gastroenterol 2016;16:82. [PMID: 27472988 DOI: 10.1186/s12876-016-0501-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Van Limbergen J, Haskett J, Griffiths AM, Critch J, Huynh H, Ahmed N, deBruyn JC, Issenman R, El-Matary W, Walters TD, Kluthe C, Roy ME, Sheppard E, Crandall WV, Cohen S, Ruemmele FM, Levine A, Otley AR. Toward enteral nutrition for the treatment of pediatric Crohn disease in Canada: a workshop to identify barriers and enablers. Can J Gastroenterol Hepatol 2015;29:351-6. [PMID: 26076398 DOI: 10.1155/2015/509497] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
4 Sugita N, Watanabe K, Kamata N, Yukawa T, Otani K, Hosomi S, Nagami Y, Tanaka F, Taira K, Yamagami H, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Kabata D, Shintani A, Arakawa T, Fujiwara Y. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease: Adalimumab with elemental diet in Crohn. Journal of Gastroenterology and Hepatology 2018;33:631-7. [DOI: 10.1111/jgh.13969] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
5 Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T. Long-term prognosis of Japanese patients with biologic-naïve Crohn's disease treated with anti-tumor necrosis factor-α antibodies. Intest Res 2019;17:94-106. [PMID: 30508475 DOI: 10.5217/ir.2018.00048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wellens J, Vermeire S, Sabino J. Let Food Be Thy Medicine-Its Role in Crohn's Disease. Nutrients 2021;13:832. [PMID: 33802429 DOI: 10.3390/nu13030832] [Reference Citation Analysis]
7 Ishihara S, Tada Y, Kawashima K, Kataoka M, Sonoyama H, Yamashita N, Oka A, Kusunoki R, Fukuba N, Mishima Y, Oshima N, Moriyama I, Yuki T, Kinoshita Y. Serum amyloid A level correlated with endoscopic findings in patients with Crohn's disease-Possible biomarker for evaluating mucosal healing. Dig Liver Dis 2018;50:553-8. [PMID: 29311027 DOI: 10.1016/j.dld.2017.12.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
8 Hirai F, Ishida T, Takeshima F, Yamamoto S, Yoshikawa I, Ashizuka S, Inatsu H, Mitsuyama K, Sou S, Iwakiri R, Nozaki R, Ohi H, Esaki M, Iida M, Matsui T; Additional Power of Elemental Diet on Maintenance Biologics Therapy in Crohn's Disease (ADORE) Study Group. Effect of a concomitant elemental diet with maintenance anti-tumor necrosis factor-α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study. J Gastroenterol Hepatol 2019;34:132-9. [PMID: 29935082 DOI: 10.1111/jgh.14361] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
9 Levine A, Sigall Boneh R, Wine E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut 2018;67:1726-38. [DOI: 10.1136/gutjnl-2017-315866] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 25.3] [Reference Citation Analysis]
10 Goens D, Micic D. Role of Diet in the Development and Management of Crohn's Disease. Curr Gastroenterol Rep 2020;22:19. [PMID: 32185530 DOI: 10.1007/s11894-020-0755-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Sood A, Singh A, Sudhakar R, Midha V, Mahajan R, Mehta V, Gupta YK, Kaur K. Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience. Intest Res 2020;18:184-91. [PMID: 32092799 DOI: 10.5217/ir.2019.00094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Hisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group. Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. Intest Res 2018;16:494-8. [PMID: 30090050 DOI: 10.5217/ir.2018.16.3.494] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
13 Qian G, Hongxia D, Jin LI. [Neutrophil-lymphocyte ratio at 14th week predicts loss of response to 52-week infliximab therapy in patients with Crohn's disease]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:453-8. [PMID: 32895126 DOI: 10.12122/j.issn.1673-4254.2020.04.01] [Reference Citation Analysis]
14 Li Y, Pan J, Zhou N, Fu D, Lian G, Yi J, Peng Y, Liu X. A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters. Scand J Gastroenterol 2021;56:1030-9. [PMID: 34304688 DOI: 10.1080/00365521.2021.1939411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Zhang QW, Shen J, Zheng Q, Ran ZH. Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta‐analysis. J Dig Dis 2019;20:65-72. [DOI: 10.1111/1751-2980.12698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Andersen V, Hansen AK, Heitmann BL. Potential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease. Nutrients 2017;9:E286. [PMID: 28294972 DOI: 10.3390/nu9030286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]